$144 Million is the total value of SV Health Investors, LLC's 9 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2020 | ||||||||
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- SVLSF VI, LLC #1
- SV Life Sciences Fund VI (GP), L.P. #2
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TRANSENTERIX, INC. | 27 | Q4 2020 | 24.0% |
| OCULAR THERAPEUTIX, INC. | 24 | Q2 2020 | 35.9% |
| KALVISTA PHARMACEUTICALS INC | 17 | Q4 2020 | 31.0% |
| DECIPHERA PHARMACEUTICALS INC | 17 | Q3 2021 | 31.0% |
| CATABASIS PHARMACEUTICALS, INC. | 15 | Q4 2018 | 18.2% |
| X4 PHARMACEUTICALS INC | 15 | Q3 2022 | 3.2% |
| BICYCLE THERAPEUTICS PLC | 14 | Q3 2022 | 65.4% |
| SUTRO BIOPHARMA INC | 14 | Q4 2021 | 19.1% |
| ENTELLUS MED INC | 12 | Q4 2017 | 64.4% |
| AVROBIO INC | 12 | Q1 2021 | 41.6% |
View SV Health Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-07 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-15 |
| 13F-HR | 2021-08-16 |
| 13F-HR | 2021-05-17 |
| 13F-HR | 2021-02-16 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-14 |
View SV Health Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.